[Skip to Content]
[Skip to Content Landing]
Editorial
January 2018

Natriuretic Peptide Deficiency—When There Is Too Little of a Good Thing

Author Affiliations
  • 1Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
JAMA Cardiol. 2018;3(1):7-9. doi:10.1001/jamacardio.2017.4208

In 1981, de Bold et al1 described a substance in rat atria that elicited a brisk natriuretic and diuretic response when infused into normal rats.1 They subsequently isolated and purified this substance, calling it atrial natriuretic factor (it is now known as atrial natriuretic peptide [ANP]). The discovery of ANP and the closely-related B-type natriuretic peptide (BNP) established the important endocrine function of the heart. The natriuretic peptide hormones promote a variety of actions that reduce cardiac load including vasodilation, natriuresis, and inhibition of the renin-angiotensin-aldosterone system. Thus, via secretion of ANP and BNP, the heart contributes to the regulation of its own wall stress, as well as systemic blood pressure and salt homeostasis. A growing body of evidence also suggests that the natriuretic peptides have favorable effects on fat metabolism and glucose handling.2

×